Targeting α-synuclein: Therapeutic options

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Alpha-synuclein (αSyn) aggregation is central to Parkinson's disease (PD) pathogenesis.
• Novel PD models utilize viral vectors or toxic αSyn species to study neurodegeneration.
• These models enhance understanding of PD mechanisms and preclinical therapeutic development.

Purpose of the Study:

• To summarize recent advances in Parkinson's disease research focusing on αSyn.
• To discuss emerging preclinical therapeutic strategies targeting αSyn.
• To explore challenges and future directions in PD and synucleinopathy research.

Main Methods:

• Review of current literature on αSyn-based PD models.
• Analysis of therapeutic strategies targeting αSyn proteotoxicity.
• Discussion of cellular clearance mechanisms (lysosomal-autophagic, proteasome) and immunization.

Main Results:

• Viral vector and αSyn inoculation models provide insights into PD neurodegeneration.
• Therapeutic strategies focus on inhibiting αSyn proteotoxicity.
• Enhancing cellular clearance pathways and immunization are promising approaches.

Conclusions:

• Advances in αSyn models offer significant promise for PD and synucleinopathy therapeutics.
• Targeting proteotoxic mechanisms of αSyn is crucial for developing neuroprotective and restorative strategies.
• Continued research efforts are vital for addressing ongoing challenges in PD treatment.